Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.32 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222533 | 0.78 | TSHR (0.40) | TRPV4CYP11B2CYP11B1EGLN2 | |
| SCHEMBL2655367 | 0.78 | TRPV4 (0.39) | TRPV4CYP11B2CYP11B1EGLN2 | |
| SCHEMBL1312049 | 0.78 | ESR1 (0.37) | TRPV4ESR1ESR2 | |
| SCHEMBL4478973 | 0.78 | CYP11B2 (0.40) | TRPV4CYP11B2CYP11B1ESR1ESR2 | |
| SCHEMBL365967 | 0.78 | TRPV4 (0.46) | TRPV4CYP11B2CYP11B1ESR1ESR2 | |
| SCHEMBL6651902 | 0.77 | TRPV4 (0.48) | TRPV4CYP11B2CYP11B1EGLN2BCAT1 | |
| SCHEMBL20607852 | 0.75 | TRPV4 (0.33) | TRPV4 | |
| SCHEMBL15421833 | 0.75 | AR (0.42) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL3838194 | 0.74 | TRPV4 (0.39) | TRPV4CYP11B2CYP11B1EGLN2 | |
| SCHEMBL9490088 | 0.74 | TRPV4 (0.43) | TRPV4CYP11B2CYP11B1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014152431-A1 | STABILIZATION OF RADIOIODINATED AND ASTATINATED PHARMACEUTIALS AND IMAGING AGENTS | Ground Fluor Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275539-A1 | STABILIZATION OF RADIOIODINATED AND ASTATINATED PHARMACEUTICALS AND IMAGING AGENTS | Ground Fluor Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275539-A1 | STABILIZATION OF RADIOIODINATED AND ASTATINATED PHARMACEUTICALS AND IMAGING AGENTS | TTR, SSTR4, RNF114 | TRPV4 4237/4885CYP11B2 2627/4885CYP11B1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.